when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

NOVARTIS · news · pharmadog

← back to NOVARTIS

News mentioning NOVARTIS

235 stories

Aug 11, 26AbbVie, Novartis and Bristol Myers file 340B lawsuits in Illinoisendpoints

Aug 11, 26STAT+: Trump is counting on the health care industry to remake vaccines. It’s pushing back insteadstat

Aug 11, 26FDA rejects ITM Isotope’s radiopharma therapy over manufacturing issuesbiospace

Aug 11, 26Amgen lays groundwork for new R&D center in Hyderabadfiercebiotech

Aug 11, 26STAT+: Pharmalittle: We’re reading about an FDA rejection, 340B court battles, and morestat

Aug 11, 26Deerfield-backed Boulevard Bio embarks on ‘beautiful path to a cure’ with trio of immunology drugsfiercebiotech

Aug 11, 26Epicrispr lands $90M to advance epigenetic editing drug for rare muscle diseasebiopharma dive

Aug 11, 26STAT+: Skylark Bio kicks off new gene therapy trial for deafnessstat

Aug 11, 26Epicrispr raises $90M to rewrite treatment of rare muscle diseasefiercebiotech

Aug 11, 26IRBs have a problem. Can North Star’s nonprofit model save it?stat

Aug 10, 26FDA rejects ITM's radiopharma drug over manufacturing problemsendpoints

Aug 10, 26BMS picks Texas for new $2.3B manufacturing campusbiospace

Aug 10, 26STAT+: In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatmentstat

Aug 10, 26STAT+: FDA panel to weigh Grail’s Galleri teststat

Aug 10, 26ITM neuroendocrine tumor drug spurned by FDA over manufacturing qualmsfiercebiotech

Aug 10, 26Labcorp nabs FDA green light for BRAF melanoma diagnosticfiercebiotech

Aug 6, 26BioVie shares halve on murky Parkinson’s disease readoutbiospace

Aug 5, 264 potential biotech M&A targets, plus a pretty sure bet from J&Jbiospace

Aug 4, 26J&J pharma leader to retire; Krystal slumps on gene therapy missbiopharma dive

Aug 4, 26Icon inks Anthropic partnership to deploy Claude into clinical trialsfiercebiotech

Aug 4, 26Vertex unfazed by competitive IgAN space as FDA verdict loomsbiospace

Aug 3, 26FDA expands Pluvicto label, making it available to most metastatic prostate cancer patientsendpoints

Aug 3, 26Curium strikes up to $8B deal for radiopharma rival Lantheusfiercebiotech

Aug 3, 26Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad ideafiercebiotech

Aug 3, 26Recon: AstraZeneca, BMS discuss merger; FDA broadens indication for Novartis’ Pluvictoraps

Jul 31, 26Trump administration tries again to institute rebates in 340Bbiopharma dive

Jul 31, 26Moderna maintains 10% growth target despite Phase 3 norovirus missbiospace

Jul 30, 26GSK pens $110M biological datasets pact with AI biotech Relationfiercebiotech

Jul 30, 26Biogen validated the Alzheimer’s tau theory. CEO Viehbacher still isn’t betting the storebiospace

Jul 29, 26Processa acquires Vidya for potential BTK inhibitor rival to Novartis’ Rhapsidofiercebiotech

← prevpage 5 of 8next →